In a groundbreaking study published in the prestigious JAMA Health Forum, researchers from the University of British Columbia have illuminated the profound financial benefits of British Columbia’s universal, no-cost prescription contraception policy, which took effect in April 2023. This pioneering research sheds light on how eliminating out-of-pocket costs for contraception radically transforms access and financial security for patients, especially young adults navigating precarious insurance coverage gaps.
Prior to the policy’s implementation, contraceptive expenses posed a substantial economic burden on individuals, with common birth control pills averaging approximately $25 per month. More invasive, long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) bore staggering upfront costs ranging from $75 to over $500. When evaluated over a lifetime, expenses for consistent pill users could reach an alarming $10,000. These costs often translated to significant barriers, especially for younger adults who are less likely to have comprehensive insurance coverage.
Analysis of pharmacy data spanning all ten Canadian provinces revealed an astounding statistic: nearly 40% of prescription contraception was financed out-of-pocket, the highest rate among any class of prescription drugs in the country. Among individuals in their twenties—a demographic acutely vulnerable to insurance gaps—the rate was even higher, nearing 45%. The introduction of universal coverage precipitated a dramatic decline, reducing the patient out-of-pocket share by roughly 33 percentage points for this group alone, and reducing it below 10% for all patient demographics overall.
Lead author Dr. Elizabeth Nethery, a postdoctoral researcher specializing in pharmaceutical sciences at UBC, highlights the importance of this policy’s timing and target population. “Individuals in their twenties are navigating a critical coverage gap, often off parental health plans and not yet enrolled in employer benefits,” she explained. “Our findings demonstrate that removing financial barriers through universal coverage specifically benefits this demographic, enabling more equitable access to effective contraceptive methods.”
In addition to patient savings, the study investigated system-wide cost implications. Surprisingly, despite the sharp decline in personal expenditures, overall contraceptive spending—including contributions by insurers and public health systems—remained stable over the two-year observation period. This finding underscores the efficiency of universal coverage interventions: reducing financial strain on individuals without inflating total healthcare costs. Furthermore, the researchers observed heightened adoption rates of LARCs, such as IUDs and implants, which offer enhanced efficacy in preventing unintended pregnancies.
Senior author Dr. Laura Schummers, assistant professor at UBC, emphasizes this research as robust evidence for the public health impact of universal contraception coverage. “Our data reveal that eliminating cost-sharing significantly increases uptake of highly effective contraceptive options,” she noted. “This not only reduces unintended pregnancies, which disproportionately affect economically disadvantaged individuals but also addresses broader social inequities tied to reproductive health access.”
In Canada, unintended pregnancies constitute approximately 40% of all pregnancies, with marginalized populations facing amplified health, educational, and economic consequences. By mitigating financial impediments to contraception, policies like British Columbia’s universal coverage program represent a critical strategic intervention in public health, economic equality, and social justice.
Momentum for universal contraception coverage is rapidly gaining traction nationwide. Manitoba launched a comparable program in October 2024, with preliminary data mirroring the cost savings and increased uptake patterns observed in British Columbia. Concurrently, at the federal level, legislative action post-2024 has confirmed a commitment to pharmacare programs encompassing contraception coverage. However, implementation agreements currently extend to only three provinces and a single territory, underscoring both progress and the necessity for expanded collaboration.
The methodology underpinning these findings derives from rigorous statistical analysis of comprehensive pharmacy dispensing data, enabling precise quantification of patient-level cost impacts over an extended time horizon. This approach distinguishes the study as the first quantitative assessment of universal contraception’s financial ramifications post-policy rollout, providing vital evidence for health economists, policymakers, and clinicians advocating for equitable reproductive healthcare.
The multidisciplinary research team encompasses esteemed institutions beyond UBC, including collaborators from the University of Calgary, University of Manitoba, Simon Fraser University, and the University of Ottawa. This diverse expertise enriches the study’s robustness and lends national relevance to its conclusions, reflecting Canada’s broader healthcare landscape.
Moreover, the research addresses a critical gap in health economics literature, which has historically underestimated the direct financial burdens imposed by contraceptive costs on individuals, especially younger cohorts. By capturing real-world data in a natural policy experiment setting, the study offers compelling justification for scaling similar initiatives across provinces and territories to reduce inequality and improve public health outcomes.
Overall, this pioneering work exemplifies how targeted, evidence-based policy interventions can reconcile economic sustainability with enhanced health equity. The British Columbia experience not only charts a course for universal pharmacare programs but also redefines contraception coverage as a foundational component of social health infrastructure.
Subject of Research: Not applicable
Article Title: Universal free contraception policy impacts on out-of-pocket payments and contraception costs
News Publication Date: 29-May-2026
Web References:
https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1269
References:
CIHR-funded study, involving researchers from UBC, University of Calgary, University of Manitoba, Simon Fraser University, and University of Ottawa.
Keywords:
Birth control, Drug costs, Pharmaceuticals, Universal coverage, Contraception policy, Health economics, Reproductive health, Out-of-pocket payments, Long-acting reversible contraceptives (LARCs), Health equity, Public health policy, Pharmacare
